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Abstract
Some colorectal cancer (CRC) patients present symp-
toms of bowel obstruction, which is considered a surgi-
cal emergency. Because of poor medical condition and 
high incidence of post-surgical complications, there 
has been increasing use of self-expanding metal stents 
(SEMS) for the purpose of palliation or as a bridge to 
surgery with some benefits, including shorter hospital 
stays, lower rates of adverse events, and one-stage 
surgery. However, with increasing survival of CRC pa-
tients, there have been controversial data on clinical 
outcomes and complications, compared between SEMS 
use and surgery for treatment of malignant bowel 
obstruction. We review recent clinical data on clinical 
outcomes of SEMS use compared to surgery, including 
complications.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: Accumulating evidence has supported the 
clinical efficacy of self-expanding metal stents (SEMS) 
placement in patients with malignant colorectal obstruc-
tion. As a bridge to surgery or a palliative measure, 
SEMS placement achieves significantly more beneficial 
short-term outcomes to relieve obstructive symptoms 
compared with emergent surgery. Furthermore, SEMS 
placement can avoid emergent surgery with stoma 
creation, which increases perioperative morbidity and 
mortality. However, the negative results of SEMS place-
ments found in recent randomized controlled trials 
should not be overlooked. For successful outcomes of 
SEMS placement, the cause of bowel obstruction, pur-
pose of intervention, life expectancy, medical condition, 
and endoscopic skill should be considered with careful 
examination on patient status.
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INTRODUCTION
Among colorectal cancer (CRC) patients, 7%-29% ini-
tially present symptoms of  bowel obstruction, such as 
vomiting, abdominal pain, and distention[1]. Because ma-
lignant bowel obstruction develops into intestinal isch-
emia or perforation, it is considered as a surgical emergen-
cy[1,2]. However, these patients are usually in poor medical 
condition and have a high incidence of  post-surgical 
complications. Despite advances in preoperative patient 
care, emergent surgical decompression results in a higher 
mortality of  15%-20% and morbidity of  45%-50% than 
elective surgery of  0.9%-6%[3,4]. In addition, up to 40% 
of  patients require a permanent colostomy after emer-
gent surgery and have low health-related quality of  life 
and increased expenses related to colostomy care[5].
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Since the first palliative use of  metal stents in the early 
1990s[6,7], there has been increasing use of  self-expanding 
metal stents (SEMS) for the palliation of  malignant 
bowel obstruction[8-12]. SEMS may be used for the pur-
pose of  palliation or as a bridge to surgery to permit one-
stage surgery at a later date. A systematic review reported 
a technical success rate of  96.2% (range, 66.6%-100%) 
and a clinical success rate of  92% (range, 46%-100%)[13]. 
In the palliative group, the median duration of  patency 
was 106 d (range, 68-288 d). Relative to emergent sur-
gery, SEMS placement had positive outcomes, including 
shorter hospital stays, and lower rates of  adverse events. 
Because of  these reasons, SEMS treatment has been 
regarded as a first-line treatment for malignant bowel 
obstruction. However, a recent Cochrane systematic re-
view including five randomized clinical trials found that 
patients receiving emergent surgery had better clinical 
success than those receiving SEMS (98.84% vs 78.05%, P 
= 0.001), and failed to show enough evidence to support 
an initial use of  SEMS for the palliation of  malignant 
colorectal obstruction, even though the SEMS group 
experienced the advantages of  shorter hospital stay and 
procedure time and lower blood loss[14]. Therefore, this 
review describes recent clinical studies of  SEMS use 
compared to surgery, focusing on clinical outcomes ac-
cording to the cause of  obstruction and the purpose of  
its use. This review includes SEMS-related complications 
and managements thereof.
MALIGNANT COLORECTAL 
OBSTRUCTION DUE TO PRIMARY 
COLORECTAL CANCER: BRIDGE TO 
SURGERY
In patients with malignant colorectal obstruction with 
curable disease, SEMS can provide a chance for one-
stage surgery with primary anastomosis after decompres-
sion (Figure 1). Without decompression, these patients 
usually receive emergent surgical resection with an os-
tomy, followed by a second operation with reanastomo-
sis. We reported a technical success rate of  97.8% and a 
clinical success rate of  94.7% for SEMS as a bridge to 
surgery[15]. Thus, for the purpose of  serving as a bridge 
to surgery, SEMS has several advantages over emergent 
surgery, including medical stabilization, full staging work-
up, conversion of  emergent to elective surgery, one-stage 
surgery with primary anastomosis, and laparoscopic ap-
proach[12,16,17].
Although several retrospective and prospective stud-
ies support these observations and suggest the primary 
use of  SEMS as a bridge to surgery[15,16,18,19], randomized 
controlled trials (RCTs) yield conflicting results. Thus 
far, six randomized controlled studies have been con-
ducted comparing the clinical efficacy of  SEMS with 
that of  emergent surgery (Table 1)[20-25]. Of  those, four 
RCTs showed favorable outcomes of  SEMS[20-22,25], while 
two RCTs reported unfavorable outcomes of  SEMS 
compared to emergent surgery[23,24]. In RCTs, the overall 
technical success rate was 78.7% (range, 46.7%-100%), 
and the overall clinical success rate was 76.7% (range, 
40%-96.7%). Interestingly, the technical and clinical suc-
cess rates of  SEMS were quite different between RCTs 
with favorable SEMS (88.8% and 87.5%, respectively) 
and unfavorable SEMS (58.5% and 55.1%, respectively). 
This may have been due to differing degrees of  experi-
ence of  endoscopists with the use of  SEMS in patients 
with malignant colorectal obstruction, as the two RCTs 
with unfavorable outcomes of  SEMS had been con-
ducted in multi-center trials, including several academic 
and community teaching hospitals, while the four RCTs 
with favorable SEMS outcomes had been conducted in a 
single center. Other factors, including different degree of  
obstruction and tumor biology may influence the results. 
One multicenter RCT by Pirlet et al[23] enrolled 60 patients 
in nine centers, and SEMS were inserted endoscopically 
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A B
Figure 1  Self-expandable metallic stent placement for acute left-side malignant obstruction. A: Fluoroscopy showed a malignant stricture with 3 cm length at a 
rectosigmoid junction. A guide wire was passed through the stricture; B: A 8 cm uncovered stent was successfully inserted and deployed.
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tal stay, the median time to starting chemotherapy, and 
stoma creation rate were significantly lower in the SEMS 
group than in the surgery group. From these two reports, 
although the overall complication rates did not differ 
between the two groups, the procedure-related mortality 
rate was significantly higher in surgery group than stent 
group.
Two recent meta-analyses reported conflicting results 
on the clinical efficacy of  SEMS compared with that 
of  surgery. One meta-analysis reported a 93.9% clinical 
success rate for SEMS[32]. Although the long-term com-
plications were significantly higher in the SEMS group 
than in the surgery group, the short-term complications 
and mortality were not different, and the hospital stay 
was significantly shorter in the SEMS group. Another 
meta-analysis showed that the SEMS group had sig-
nificantly lower clinical success than the surgery group 
(93.1% vs 99.8%)[33]. Although the overall complications 
did not differ (34.0% vs 38.1%), the 30-d mortality was 
significantly lower in the SEMS group than in the sur-
gery group (4.2% vs 10.5%). Hospital stay (9.6 d vs 18.8 
d), time to initiation of  chemotherapy (15.5 d vs 66.4 d), 
and stoma formation (12.7% vs 54.0%) were significantly 
lower in the SEMS group than in the surgery group.
Because most studies focused on the clinical out-
comes of  SEMS, the oncologic outcomes of  SEMS for 
the purpose of  palliation were not clearly established. 
We reported that the median time to progression (7.97 
mo vs 7.40 mo) and the median overall survival (10.9 
mo vs 13.0 mo) did not differ between the SEMS group 
and the surgery group[11]. Although the time to the first 
chemotherapy was definitely shorter in the SEMS group 
than in the surgery group, this might not affect survival. 
Another retrospective study supported our result[29]. 
They reported no difference in overall survival between 
SEMS and surgery (14 mo vs 11 mo). However, a recent 
retrospective study reported a poor oncologic outcome 
of  an SEMS group compared to a surgery group[31]. Al-
though they showed clinical efficacies for SEMS place-
ment comparable to previous studies, the median overall 
survival was significantly shorter in the SEMS group 
than the surgery group (7.6 mo vs 15.9 mo). The authors 
explained this by the effect of  primary tumor resection. 
They reported that all of  the patients underwent pri-
mary tumor resection. However, this explanation is not 
supported by the fact that in our study, 89% of  patients 
underwent primary tumor resection, yet there was no 
difference in overall survival between the two groups [11]. 
Moreover, they included only 36 patients in the SEMS 
group, and more patients with American Society of  
Anesthesiologists (ASA) III and IV in the SEMS group 
than in the surgery group. These differences may influ-
ence their results. A recent meta-analysis also found no 
difference in the overall survival rate between SEMS and 
surgery (7.64 mo vs 7.88 mo)[33].
It is evident that the early clinical efficacy of  SEMS is 
comparable to that of  surgery and that the rate of  early 
stent-related complications is acceptable. Although a 
previous multicenter RCT with Wall Flex stents reported 
an unexpectedly high rate of  stent perforation[34], this 
observation was not observed in other studies with the 
same stents[35,36]. Thus, the perforations may have been 
attributable to endoscopic factors. Although long-term 
patent duration with SEMS is shorter than with surgery 
due to stent-related complications, repeated stent place-
ments can overcome this limitation. Therefore, SEMS 
is one of  therapeutic optionsfor palliation of  malignant 
colorectal obstruction in patients with incurable disease, 
based on the life expectancy and surgical risk.
SECONDARY COLORECTAL 
OBSTRUCTION DUE TO EXTRA-COLONIC 
TUMOR
Colonic obstructions may also occur from compression 
or invasion by extra-colonic tumors. The etiology for 
obstruction by extrinsic cancer includes metastatic or 
far-advanced gastric, gynecologic, pancreatic, bladder, or 
small bowel tumors, and a location of  obstruction relat-
ed to the primary tumor’s location, such as transverse co-
lon obstruction in the case of  gastric cancer, because of  
anatomical proximity[37]. In these cases, the patients may 
be in state of  carcinomatosis and have adhesions due to 
prior surgery or chemoradiation. Therefore, the colon 
may have complex strictures and be immobilized, which 
means that the bowel is not movable during the colo-
noscopy. In this setting, considering the poor prognosis, 
short life expectancy, and high mortality and morbidity 
rate associated with palliative surgery, colorectal stenting 
could be an alternative therapeutic option instead of  pal-
liative surgery[38,39].
Because the obstruction pattern and tumor charac-
teristics related to extra-colonic tumor are different from 
those of  primary colorectal cancer, the results of  stent 
insertion are expected to be different. However, there 
have been limited data on the use of  colorectal stents in 
patients with extra-colonic tumor-related obstruction.
The reported success rates of  SEMS in colorectal ob-
struction by extra-colonic tumor vary. Shin et al[37] report-
ed favorable technical and clinical success rates for SEMS 
(87.2% and 82.1%, respectively), which are comparable 
with previous data on obstruction by primary colorectal 
cancer[40,41], and Kim et al[42] also found favorable techni-
cal and clinical success rates (90.0% and 85.0%, respec-
tively) in treating colorectal obstruction by non colonic 
malignancy with peritoneal carcinomatosis via SEMS. 
However, Keswani et al[43] reported significantly lower 
technical and clinical success rates (66.7% and 20.0%, 
respectively) in cases of  extra-colonic obstruction than 
in primary colorectal cancer (97.1% and 88.6%, respec-
tively). However, these reports are derived from differ-
ent patient settings, including different distributions of  
primary tumor etiology and locations of  obstructions. 
Therefore, the heterogeneity of  tumor origins and selec-
tion bias by selected inclusion could cause differences in 
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the success rates for SEMS in colorectal obstruction by 
extra-colonic tumor. In addition, there could be many 
possible etiologies for technical failure, such as the in-
ability to pass the guidewire through the obstruction site 
due to sharply angulated, tortuous, and fixed intestinal 
segments, and colonic immobilization due to adhesions 
and peritoneal seedings, which make it difficult to access 
the obstructive lesion during stent insertion. Another 
consideration that could account for a low clinical suc-
cess rate is the failure to decompress bowel obstructions 
after successful stenting in the case of  extensive com-
pression by extrinsic mass or multifocal strictures caused 
by carcinomatosis. In addition, Kim et al[44] reported that, 
in patients with extra-colonic obstruction by advanced 
gastric cancer, SEMS insertion seemed to be less effec-
tive than emergency surgery for palliation of  colorectal 
obstruction. Therefore, careful examination of  various 
imaging studies and of  the patient’s condition to obtain 
accurate information would be necessary before decid-
ing between stent insertion and surgery.
As for the complications of  SEMS in extra-colonic 
tumor-related obstruction, such as migration, resteno-
sis, and perforation, Shin et al[37] and Kim et al[42] found 
rates and patterns similar to those of  SEMS in primary 
colorectal cancer. However, Keswani et al[43] reported a 
significantly higher risk of  SEMS complications, includ-
ing death, than in patients with primary colorectal can-
cer. With regard to stent migration, it has been proposed 
that the smoother and less fixable surface of  the colon 
wall caused by extrinsic tumors might increase migra-
tion of  covered stents, suggesting that uncovered stents 
might be suitable for colorectal obstructions caused by 
an extrinsic tumor[37].
However, all these data on success rates and com-
plications have been from limited studies with small 
heterogeneous patient groups, and thus, further evalua-
tion of  the role of  SEMS in extra-colonic tumor-related 
bowel obstruction should be performed in large retro-
spective analyses or randomized, prospective studies to 
definitively determine the outcomes and complications 
of  SEMS versus surgery.
OVERCOMING STENT-RELATED 
COMPLICATIONS
A previous meta-analysis found that reobstruction rates 
were 12% (range, 1%-92%), migration rates 11% (range, 
0%-50%), and perforation rates 4.5% (range, 1%-92%). 
A recent meta-analysis including only incurable malig-
nant colorectal obstruction reported a 10.1% perforation 
rate, a 9.2% migration rate, and an 18.3% reobstruction 
rate[13,41]. A recent cohort study with 382 patients report-
ed a 3.9% perforation rate, a 1.8% migration rate, a 2.1% 
reobstruction rate, and a 0.5% bleeding rate within 30 d 
after SEMS placement[36]. In our institution, we reported 
a 4.0% perforation rate, 9.0% migration rate, and a 22.9% 
reobstruction rate after successful stent placement[15]. 
Thanks to modern polychemotherapy combined with 
targeted agents, the survival of  patients with unresectable 
CRCs has lengthened from 11-13 mo to 14.8-21.5 mo[45]. 
Therefore, the chance to develop stent-related complica-
tions in patients with CRCs after successful stenting has 
increased concomitantly.
Of  the possible stent-related complications, perfora-
tion is the most disastrous. Stent-related perforation can 
occur during the procedure, which is primarily due to 
factors related to the endoscopist, or in the follow-up 
period, in which case it is related to stent factors and che-
motherapeutic agents. A recent meta-analysis including 
malignant and benign strictures found a 7.4% perfora-
tion rate[46]. Dilation after stent placement significantly 
increased the risk of  perforation, to 20.4%. Although 
chemotherapy without bevacizumab showed a similar risk 
of  perforation, bevacizumab-based therapy significantly 
increased the risk of  perforation, to 12.5%.
Colon stents are classified into uncovered stents and 
covered stents. Our previous study showed that the me-
dian duration of  first stent patency was 137 d (range, 
14-1217 d) in patients with unresectable colorectal can-
cers[11]. However, during the follow-up period, 29.6% of  
patients developed reobstruction due to stent migration, 
tumor outgrowth, or ingrowth. In light of  this finding, 
covered stents have been developed to reduce reobstruc-
tion by blocking tumor ingrowth.
There have been a few studies to compare the clinical 
efficacies of  uncovered stents with covered stents. Park 
et al[16] conducted a randomized prospective single center 
study to compare the clinical efficacies of  uncovered 
WallFlex stents (Boston Scientific Co) and covered Com-
vi stents (Taewoong Medical Co) in 151 patients with ma-
lignant colorectal obstruction. Among 151 patients, 120 
had primary colorectal cancer and 31 had extra-colonic 
malignancies. Technical (98.7% vs 98.7%) and clinical suc-
cess rates (92.0% vs 95.9%) were not statistically different 
between the WallFlex group and the Comvi stent group. 
Stent reobstruction due to tumor infiltration tended to be 
high with WallFlex stents compared to with Comvi stents 
(14.5% vs 3.8%). However, stent migration was signifi-
cantly higher with Comvi stents than with WallFlex stents 
(21.1% vs 1.8%). Stent patency did not differ between 
the two groups (6 mo with WallFlex stent vs 7.3 mo with 
Comvi stents). Therefore, although covered stents were 
developed to reduce stent reobstruction by theoretically 
blocking tumor infiltration and increasing stent patency, 
this recent study failed to show any clinical advantage of  
covered stents, which had a high incidence of  stent mi-
gration.
Primary colectomy after successful stent placement 
could be a therapeutic option in patients with unresect-
able CRCs to prevent long-term complications of  SEMS. 
Our data found that 14 of  130 patients with unresectable 
obstructive CRCs underwent further primary colectomy 
after successful stent placement[47]. Up to 44.6% of  pa-
tients experienced long-term complications with SEMS, 
and multivariate analysis revealed that primary colectomy 
after successful endoscopic stent placement significantly 
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reduced the risk of  reobstruction. Therefore, primary 
colectomy after successful endoscopic stent placement 
could be an alternative therapeutic option in unresect-
able CRC patients, especially those who expect long-
term survival.
Patients with SEMS experience reobstruction at a rate 
of  up to 30%[11,13,41]. In these cases, second stent place-
ment is one of  the therapeutic options for palliation of  
reobstruction (Figure 2). As mentioned above, the median 
patent duration of  SEMS including second stent place-
ment was similar to that of  surgery[11]. Our recent study 
including 79 patients with second SEMS and 36 patients 
with palliative surgery after reobstruction showed a 
97.5% technical success rate and 86.1% clinical success 
rate for SEMS[48]. Although clinical outcomes were bet-
ter in palliative surgery, procedure-related mortality oc-
curred only in palliative surgery. Therefore, second stent 
placement should be considered as an alternative treat-
ment to relieve malignant colorectal reobstruction, and 
palliative surgery should be considered for patients who 
have good performance and expect long-term survival.
CONCLUSION
Accumulating evidence has supported the clinical efficacy 
of  SEMS placement in patients with malignant colorectal 
obstruction. As a bridge to surgery or a palliative measure, 
SEMS placement achieves significantly more beneficial 
short-term outcomes to relieve obstructive symptoms 
compared with emergent surgery. Furthermore, SEMS 
placement can avoid emergent surgery with stoma creation, 
which increases perioperative morbidity and mortality.
However, the negative results of  SEMS placements 
found in recent RCTs should not be overlooked[24,34]. 
Most of  the retrospective and prospective studies with 
positive results for SEMS placements were performed in 
large volume centers with experienced endoscopists. Ex-
tensive studies on the prerequisites for successful SEMS 
placement are required. In cases of  colorectal obstruc-
tion by extra-colonic tumor, because there is insufficient 
evidence to support the benefit of  SEMS with respect to 
success rate and complications, SEMS could be indicated 
in cases where decompressive surgery is not feasible.
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